FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311806323> ?p ?o ?g. }

• W4311806323 endingPage "e005934" @default.
• W4311806323 startingPage "e005934" @default.
• W4311806323 abstract "Current Food and Drug Administration (FDA)-approved CD19-specific chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies are constitutively active and while efficacious, can cause morbidity and mortality. Their toxicities might be reduced if CAR T-cell activity was regulatable rather than constitutive. To test this, we compared the efficacies and morbidities of constitutively active (conventional) and regulatable (switchable) CAR (sCAR) T-cells specific for human CD19 (huCD19) in an immune-competent huCD19+ transgenic mouse model.Conventional CAR (CAR19) and sCAR T-cells were generated by retrovirally transducing C57BL/6 (B6) congenic T-cells with constructs encoding antibody-derived single chain Fv (sFv) fragments specific for huCD19 or a peptide neoepitope (PNE), respectively. Transduced T-cells were adoptively transferred into huCD19 transgenic hemizygous (huCD19Tg/0 ) B6 mice; healthy B-cells in these mice expressed huCD19Tg Prior to transfer, recipients were treated with a lymphodepleting dose of cyclophosphamide to enhance T-cell engraftment. In tumor therapy experiments, CAR19 or sCAR T-cells were adoptively transferred into huCD19Tg/0 mice bearing a syngeneic B-cell lymphoma engineered to express huCD19. To regulate sCAR T cell function, a switch protein was generated that contained the sCAR-specific PNE genetically fused to an anti-huCD19 Fab fragment. Recipients of sCAR T-cells were injected with the switch to link sCAR effector with huCD19+ target cells. Mice were monitored for survival, tumor burden (where appropriate), morbidity (as measured by weight loss and clinical scores), and peripheral blood lymphocyte frequency.CAR19 and sCAR T-cells functioned comparably regarding in vivo expansion and B-cell depletion. However, sCAR T-cells were better tolerated as evidenced by the recipients' enhanced survival, reduced weight loss, and improved clinical scores. Discontinuing switch administration allowed healthy B-cell frequencies to return to pretreatment levels.In our mouse model, sCAR T-cells killed huCD19+ healthy and malignant B-cells and were better tolerated than CAR19 cells. Our data suggest sCAR might be clinically superior to the current FDA-approved therapies for B-cell lymphomas due to the reduced acute and chronic morbidities and mortality, lower incidence and severity of side effects, and B-cell reconstitution on cessation of switch administration." @default.
• W4311806323 created "2022-12-28" @default.
• W4311806323 creator A5008953239 @default.
• W4311806323 creator A5010964073 @default.
• W4311806323 creator A5027213116 @default.
• W4311806323 creator A5031807330 @default.
• W4311806323 creator A5045254198 @default.
• W4311806323 creator A5051765438 @default.
• W4311806323 creator A5052769446 @default.
• W4311806323 creator A5055928297 @default.
• W4311806323 creator A5058268746 @default.
• W4311806323 creator A5063139365 @default.
• W4311806323 date "2022-12-01" @default.
• W4311806323 modified "2023-10-09" @default.
• W4311806323 title "Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19⁺malignancy" @default.
• W4311806323 cites W1544331058 @default.
• W4311806323 cites W1902350933 @default.
• W4311806323 cites W1966542058 @default.
• W4311806323 cites W1985579610 @default.
• W4311806323 cites W2007296317 @default.
• W4311806323 cites W2028460943 @default.
• W4311806323 cites W2051549641 @default.
• W4311806323 cites W2066186103 @default.
• W4311806323 cites W2084825289 @default.
• W4311806323 cites W2118796952 @default.
• W4311806323 cites W2130338247 @default.
• W4311806323 cites W2145985838 @default.
• W4311806323 cites W2233225245 @default.
• W4311806323 cites W2346100215 @default.
• W4311806323 cites W2587691649 @default.
• W4311806323 cites W2796175343 @default.
• W4311806323 cites W2885674199 @default.
• W4311806323 cites W2899273306 @default.
• W4311806323 cites W3102474194 @default.
• W4311806323 cites W3133429828 @default.
• W4311806323 cites W3157520262 @default.
• W4311806323 cites W4210589143 @default.
• W4311806323 cites W4220655611 @default.
• W4311806323 cites W4234802323 @default.
• W4311806323 cites W4281984900 @default.
• W4311806323 doi "https://doi.org/10.1136/jitc-2022-005934" @default.
• W4311806323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36521930" @default.
• W4311806323 hasPublicationYear "2022" @default.
• W4311806323 type Work @default.
• W4311806323 citedByCount "2" @default.
• W4311806323 countsByYear W43118063232023 @default.
• W4311806323 crossrefType "journal-article" @default.
• W4311806323 hasAuthorship W4311806323A5008953239 @default.
• W4311806323 hasAuthorship W4311806323A5010964073 @default.
• W4311806323 hasAuthorship W4311806323A5027213116 @default.
• W4311806323 hasAuthorship W4311806323A5031807330 @default.
• W4311806323 hasAuthorship W4311806323A5045254198 @default.
• W4311806323 hasAuthorship W4311806323A5051765438 @default.
• W4311806323 hasAuthorship W4311806323A5052769446 @default.
• W4311806323 hasAuthorship W4311806323A5055928297 @default.
• W4311806323 hasAuthorship W4311806323A5058268746 @default.
• W4311806323 hasAuthorship W4311806323A5063139365 @default.
• W4311806323 hasBestOaLocation W43118063231 @default.
• W4311806323 hasConcept C153911025 @default.
• W4311806323 hasConcept C159654299 @default.
• W4311806323 hasConcept C203014093 @default.
• W4311806323 hasConcept C2776090121 @default.
• W4311806323 hasConcept C2778957590 @default.
• W4311806323 hasConcept C3875195 @default.
• W4311806323 hasConcept C502942594 @default.
• W4311806323 hasConcept C71924100 @default.
• W4311806323 hasConcept C86803240 @default.
• W4311806323 hasConcept C8891405 @default.
• W4311806323 hasConcept C90375314 @default.
• W4311806323 hasConceptScore W4311806323C153911025 @default.
• W4311806323 hasConceptScore W4311806323C159654299 @default.
• W4311806323 hasConceptScore W4311806323C203014093 @default.
• W4311806323 hasConceptScore W4311806323C2776090121 @default.
• W4311806323 hasConceptScore W4311806323C2778957590 @default.
• W4311806323 hasConceptScore W4311806323C3875195 @default.
• W4311806323 hasConceptScore W4311806323C502942594 @default.
• W4311806323 hasConceptScore W4311806323C71924100 @default.
• W4311806323 hasConceptScore W4311806323C86803240 @default.
• W4311806323 hasConceptScore W4311806323C8891405 @default.
• W4311806323 hasConceptScore W4311806323C90375314 @default.
• W4311806323 hasFunder F4320306156 @default.
• W4311806323 hasFunder F4320314098 @default.
• W4311806323 hasFunder F4320333173 @default.
• W4311806323 hasFunder F4320337351 @default.
• W4311806323 hasFunder F4320337355 @default.
• W4311806323 hasIssue "12" @default.
• W4311806323 hasLocation W43118063231 @default.
• W4311806323 hasLocation W43118063232 @default.
• W4311806323 hasLocation W43118063233 @default.
• W4311806323 hasOpenAccess W4311806323 @default.
• W4311806323 hasPrimaryLocation W43118063231 @default.
• W4311806323 hasRelatedWork W2730154020 @default.
• W4311806323 hasRelatedWork W2801288940 @default.
• W4311806323 hasRelatedWork W2912741252 @default.
• W4311806323 hasRelatedWork W2952578922 @default.
• W4311806323 hasRelatedWork W3211748251 @default.
• W4311806323 hasRelatedWork W40408739 @default.
• W4311806323 hasRelatedWork W4281289906 @default.

• next